The Oncology Institute Rebrands Into Starling Oncology While Its Balance Sheet Gets a Second Life

The Oncology Institute Inc (TOI) reports Q2 2026 earnings after market close on August 6, 2026, with analysts expecting a loss of $-0.07 per share—a dramatic improvement from the $-0.15 loss in the same quarter last year. The central question is whether the company's recent momentum in narrowing losses and beating estimates can continue, particularly as management executes on its 2026 guidance for positive adjusted EBITDA and expanded Medicare Advantage enrollment.

Part 1: Earnings Preview

The Oncology Institute operates value-based oncology clinics serving underserved patient populations through partnerships with payors and risk-bearing entities, focusing on capitated contracts and delegated Medicare Advantage lives. The company aims to improve health outcomes while controlling costs through its network of community-based cancer centers.

For Q2 2026, analysts expect a loss of $-0.07 per share, representing a +53.33% improvement from the $-0.15 loss reported in Q2 2025. Most recently, TOI reported Q1 2026 EPS of $-0.02, crushing the $-0.07 estimate by 71.43%. Looking ahead, the consensus calls for continued improvement with a $-0.06 loss in Q3 2026 (+57.14% year-over-year) and a full-year 2026 loss of $-0.18 (+66.67% improvement from 2025's $-0.54 loss).

Three key themes define this earnings story:

Path to Profitability: Management has reaffirmed full-year 2026 guidance targeting adjusted EBITDA of $0 to +$9 million and raised free cash flow guidance to positive $5–$15 million (up from prior outlook of −$15M to +$5M). The company guided Q2 adjusted EBITDA of −$1M to +$1M, making this quarter critical for demonstrating progress toward breakeven. Investors will scrutinize whether TOI can deliver on these targets while maintaining its trajectory of narrowing losses.

Medicare Advantage Expansion: TOI expects to expand delegated Medicare Advantage lives to approximately 200,000 across 25 counties by July 1, 2026, with roughly 7 new clinics opening this year. This expansion of capitated contract enrollment represents sustainable, recurring revenue streams that are central to the company's long-term value proposition. Commentary on payor mix, enrollment numbers, and risk-sharing revenue will be crucial for assessing market penetration.

AI-Driven Cost Savings: Management has highlighted $2 million of 2026 operating expense savings from AI initiatives, with additional upside potential from pharmacy and portal rollouts not yet included in current forecasts. How effectively TOI leverages technology to control costs while scaling operations will be a key differentiator, particularly as the company targets operating margins and adjusted EBITDA improvements.

Analyst commentary ahead of the release emphasizes the importance of monitoring patient growth, clinic count expansion, capitated contract enrollment, and any updates on payor negotiations or cost-control initiatives as indicators of both near-term profitability and long-term strategic positioning.

Part 2: Historical Earnings Performance

TOI has demonstrated improving execution over the past four quarters, with a clear trend toward narrowing losses and increasingly beating analyst expectations. The company reported $-0.15 in Q2 2025, $-0.14 in Q3 2025, $-0.06 in Q4 2025, and $-0.02 in Q1 2026—a consistent pattern of sequential improvement.

The earnings surprise pattern has turned decisively positive in recent quarters. After missing estimates by 7.14% in Q2 2025 and 16.67% in Q3 2025, TOI delivered a strong +25.00% beat in Q4 2025 and an exceptional +71.43% beat in Q1 2026. This shift suggests management is either becoming more conservative with guidance or executing better than expected on its cost-control and revenue initiatives.

The magnitude of improvement is substantial: TOI has reduced its quarterly loss by 87% from $-0.15 four quarters ago to $-0.02 most recently. If the company meets the current $-0.07 estimate for Q2 2026, it would represent a 53% improvement year-over-year, though it would mark a step back from the exceptional Q1 performance. Investors will be watching closely to see whether the Q1 beat was an outlier or part of a sustainable trend toward profitability.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TOI reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings data.

TOI exhibits high volatility around earnings, with an average absolute Day 0 move of 10.01% and Day +1 move of 13.55%—significantly elevated compared to typical stocks. The Day +1 reaction tends to be larger and more decisive than Day 0 anticipation, with an average range of 21.71% on the day following results.

The direction of moves has been mixed but increasingly positive in recent reports. The most recent earnings (May 2026) saw a strong +7.11% Day 0 move followed by a modest -1.72% Day +1 pullback. Prior to that, March 2026 showed initial weakness (-5.07% Day 0) but a powerful +8.40% Day +1 surge. The pattern suggests the market has been rewarding TOI's improving fundamentals, particularly when the company beats estimates, though reactions can be volatile and sometimes delayed to Day +1 as investors digest the details.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 10.77% for the August expiration, which aligns closely with TOI's average historical Day 0 move of 10.01% but sits well below the average Day +1 move of 13.55%. This suggests options traders may be underpricing the potential volatility, particularly given TOI's recent pattern of delivering significant post-earnings moves that often extend into the following session.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on TOI with an average rating of 4.40 out of 5.00 (Strong Buy territory), based on 5 analysts covering the stock. The breakdown shows 3 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with no sell ratings. This represents a unanimous positive tilt among analysts, reflecting confidence in the company's turnaround trajectory.

The consensus price target of $8.50 implies +65.69% upside from the current price of $5.13, with estimates ranging from a low of $7.00 (+36.45% upside) to a high of $10.00 (+94.93% upside). The wide range suggests varying views on the pace of TOI's path to profitability, though all analysts see meaningful appreciation potential.

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.40. This stability suggests analysts are maintaining conviction in their bullish thesis while waiting for TOI to execute on its 2026 guidance and demonstrate sustainable progress toward positive adjusted EBITDA and free cash flow.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 56% Buy signal, down from 72% a week ago and 100% a month ago, indicating some recent cooling in technical momentum despite the stock's longer-term uptrend. This moderation in the signal suggests consolidation or profit-taking ahead of the earnings event.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has softened from recent highs, reflecting cautious positioning ahead of earnings
• Medium-term (50% Buy): Neutral-to-positive reading suggests the intermediate trend remains constructive but lacks strong directional conviction
• Long-term (100% Buy): Strong buy signal confirms the broader uptrend remains intact, supported by the stock's substantial gains over the past year

Trend Characteristics: The combination of Good strength and Average direction suggests TOI is in a healthy uptrend but experiencing normal consolidation, creating a balanced technical setup heading into the earnings release.

TOI is trading at $5.13, positioned above its 5-day ($4.96), 10-day ($5.07), 100-day ($4.32), and 200-day ($3.86) moving averages, confirming the longer-term uptrend remains intact. However, the stock sits below its 20-day ($5.41) and 50-day ($5.16) moving averages, indicating recent near-term weakness or consolidation. The 200-day moving average has risen from lower levels, reflecting the stock's substantial recovery over the past year. The technical setup is moderately supportive heading into earnings—the longer-term trend is positive, but the recent pullback from the 20-day average suggests the market is taking a wait-and-see approach. A strong earnings beat and guidance affirmation could propel TOI back above near-term resistance, while any disappointment could test support at the 100-day average near $4.32.